View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 19, 2009

Tibotec and Gilead Combine to Develop New Antiretroviral

Tibotec Pharmaceuticals has entered into an agreement with Gilead Sciences for the development and commercialisation of a new once-daily fixed-dose antiretroviral. The complete once-daily antiretroviral treatment regimen for HIV contains Tibotec's investigational non-nucleoside reverse tr

By cms admin

Tibotec Pharmaceuticals has entered into an agreement with Gilead Sciences for the development and commercialisation of a new once-daily fixed-dose antiretroviral.

The complete once-daily antiretroviral treatment regimen for HIV contains Tibotec’s investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine hydrochloride 25mg) and Gilead’s Truvada (emtricitabine 200mg/tenofovir disoproxil fumarate 300mg).

Tibotec R&D president Roger Pomerantz said that a simplified regimen may help improve patient adherence and decrease overall pill burden.

“We are very pleased to collaborate with Gilead, one of the leading companies in the fight against HIV/AIDS, and look forward to advancing this new fixed-dose product in addition to TMC278 as a single agent,” Pomerantz said.

Tibotec is currently studying the combination of Truvada and TMC278 in a Phase III programme through two ongoing clinical trials, TMC278-C209 and TMC278-C215, which have enrolled over 1,300 treatment-naive adult patients with HIV-1.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology